Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03412045 · ClinicalTrials.gov registry record · NA
Hyperbaric Oxygen Therapy in Sickle Cell Pain
A NA study, sponsored by University of Nebraska.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT03412045 is a NA study that has completed, run by University of Nebraska. The registered enrollment target is 8 participants.
The verdict
NCT03412045, a NA study, has completed, sponsored by University of Nebraska.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
Sickle cell anemia is a genetic blood disorder where red blood cells are abnormally shaped, crescent- or sickle-shaped, instead of the normal, round shape. This misshapen cell is rigid and sticky, causing them to clump together and block small blood vessels. This blockage can lead to pain, infections, and organ damage, and the shortened lifespan of sickle cells causes anemia. The purpose of this study is to explore if hyperbaric oxygen (HBO) therapy would decrease pain and hospital length of stay associated with acute sickle cell pain crisis. Adults presenting with an uncomplicated acute pain crisis (i.e., acute chest syndrome, acute myocardial infarction/stroke) would be eligible. The intervention would be 1-3 hyperbaric oxygen sessions depending on response to therapy. Each treatment session will be approximately two hours in length. Evaluation would be through participants' self--assessment via the visual analog scale for pain level before and after treatments as well as tracking length of stay in the hospital.
Interventions
- DEVICE hyperbaric oxygen therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2022-09-01 |
| Est. Completion | 2025-06-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03412045
The ClinicalTrials.gov registry entry for NCT03412045 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Nebraska, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which hyperbaric oxygen therapy is the first listed.
NCT03412045 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03412045 about?
NCT03412045 is a clinical study titled "Hyperbaric Oxygen Therapy in Sickle Cell Pain". Sickle cell anemia is a genetic blood disorder where red blood cells are abnormally shaped, crescent- or sickle-shaped, instead of the normal, round shape. This misshapen cell is rigid and sticky, causing them to clump together and block small blood vessels. This blockage can lead to pain, infection...
What is the current status of trial NCT03412045?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2022-09-01. Estimated completion is 2025-06-05.
What interventions are being tested in trial NCT03412045?
The interventions under investigation include: hyperbaric oxygen therapy (DEVICE).
Who is sponsoring clinical trial NCT03412045?
This trial is sponsored by University of Nebraska, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.